

Nigel H Russell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8087877/publications.pdf>

Version: 2024-02-01

146
papers

6,748
citations

136740

32
h-index

62479

80
g-index

146
all docs

146
docs citations

146
times ranked

6623
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology, 2022, ,	1.2	0
2	Therapy for isocitrate dehydrogenase 2 (IDH2) ^{R172} mutant acute myeloid leukaemia. British Journal of Haematology, 2022, 196, 1348-1352.	1.2	3
3	Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial. British Journal of Haematology, 2022, 196, 1344-1347.	1.2	6
4	A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology, 2022, 196, 1337-1343.	1.2	1
5	Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1026-1030.	1.2	63
6	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 2021, 192, 853-868.	1.2	14
7	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy, 2021, 27, 153-162.	0.6	16
8	How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). British Journal of Haematology, 2021, 193, 231-244.	1.2	31
9	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	3.9	18
10	Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2021, 87, 513-523.	1.1	4
11	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of Clinical Oncology, 2021, 39, 890-901.	0.8	20
12	A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2021, 39, 7016-7016.	0.8	3
13	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 2021, 5, 5107-5111.	2.5	25
14	Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia. Leukemia Research, 2021, 108, 106553.	0.4	0
15	Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 2021, 5, 5621-5625.	2.5	11
16	Gemtuzumab ozogamicin in (KMT2A) rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials. British Journal of Haematology, 2021, ,	1.2	0
17	A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. Blood, 2021, 138, 2355-2355.	0.6	0
18	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. Bone Marrow Transplantation, 2020, 55, 613-622.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Analysis of the clinical impact of <i>NPM1</i> mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 852-859.	1.2	13
20	Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. <i>British Journal of Haematology</i> , 2020, 188, 86-100.	1.2	17
21	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
22	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. <i>Bone Marrow Transplantation</i> , 2020, 55, 1975-1984.	1.3	8
23	Molecular MRD status and outcome after transplantation in <i>NPM1</i> -mutated AML. <i>Blood</i> , 2020, 135, 680-688.	0.6	109
24	The Natural History of <i>NPM1</i> MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 25-27.	0.6	4
25	A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7520-7520.	0.8	0
26	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e616-e629.	2.2	42
27	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 984-997.	5.1	330
28	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e270-e271.	2.0	1
29	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019, 216, 966-981.	4.2	91
30	DNA damage corrects the aberrant cytoplasmic localisation of nucleophosmin in <i>NPM1</i> mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 343-347.	1.2	6
31	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 443-450.	2.0	84
32	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
33	Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. <i>Blood Advances</i> , 2019, 3, 4264-4270.	2.5	7
34	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3052-3061.	2.5	15
35	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 999-1005.	1.2	29
36	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 57-73.	5.1	245

#	ARTICLE	IF	CITATIONS
37	Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. <i>British Journal of Haematology</i> , 2019, 186, 130-133.	1.2	7
38	Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 1372-1372.	0.6	2
39	Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 737-737.	0.6	3
40	Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 382-382.	0.6	2
41	Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2648-2648.	0.6	3
42	Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial. <i>Blood</i> , 2019, 134, 2599-2599.	0.6	1
43	Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial. <i>Blood</i> , 2019, 134, 736-736.	0.6	6
44	Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family. <i>Blood</i> , 2019, 134, 3498-3498.	0.6	2
45	The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial. <i>Blood</i> , 2019, 134, 2031-2031.	0.6	4
46	Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial. <i>Blood</i> , 2019, 134, 1889-1889.	0.6	2
47	Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial. <i>Blood</i> , 2019, 134, 1910-1910.	0.6	2
48	Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Blood</i> , 2019, 134, 4374-4374.	0.6	3
49	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 24, 1657-1663.	2.0	11
50	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 930-936.	2.0	11
51	UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. <i>Journal of Clinical Apheresis</i> , 2018, 33, 46-59.	0.7	42
52	No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. <i>Blood</i> , 2018, 131, 468-471.	0.6	36
53	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	5.1	205
54	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. <i>Haematologica</i> , 2018, 103, 1654-1661.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 1486-1497.	0.8	151
56	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
57	Pre-Transplant <i>NPM1</i> Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status. <i>Blood</i> , 2018, 132, 2739-2739.	0.6	2
58	A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. <i>Blood</i> , 2018, 132, 302-302.	0.6	6
59	The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Trial. <i>Blood</i> , 2018, 132, 372-372.	0.6	2
60	Outcomes of Relapsed/Refractory Patients with <i>IDH1/2</i> Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials. <i>Blood</i> , 2018, 132, 664-664.	0.6	2
61	Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials. <i>Blood</i> , 2018, 132, 1392-1392.	0.6	2
62	Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis. <i>Blood</i> , 2018, 132, 2570-2570.	0.6	0
63	Haploidentical Transplantation Using High Dose Post-Transplant Cyclophosphamide for Patients with Aplastic Anemia : The European Group for Blood and Marrow Transplantation Experience. <i>Blood</i> , 2018, 132, 486-486.	0.6	0
64	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. <i>Blood</i> , 2018, 132, 3280-3280.	0.6	2
65	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 4390-4390.	0.6	0
66	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017, 129, 1143-1154.	0.6	125
67	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	2.0	17
68	Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide. <i>Blood</i> , 2017, 130, 904-904.	0.6	12
69	Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8009-8009.	0.8	10
70	A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells. <i>Oncotarget</i> , 2017, 8, 111405-111418.	0.8	13
71	Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with <i>t(4;11)(q21;q23)</i> <i>KMT2A/AFF1</i> (MLL/AF4) B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT). <i>Blood</i> , 2017, 130, 669-669.	0.6	0
72	Polymorphism in <i>TGFB1</i> is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. <i>Haematologica</i> , 2016, 101, 382-390.	1.7	6

#	ARTICLE	IF	CITATIONS
73	Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. <i>Blood</i> , 2016, 128, 449-452.	0.6	49
74	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. <i>British Journal of Haematology</i> , 2016, 172, 360-370.	1.2	79
75	Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the <sc>UK</sc> National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. <i>British Journal of Haematology</i> , 2016, 172, 478-481.	1.2	1
76	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m ² with 6 mg/m ² in the NCRI AML17 Trial. <i>Haematologica</i> , 2016, 101, 724-731.	1.7	60
77	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1351-1358.	1.7	70
78	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
79	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016, 374, 422-433.	13.9	662
80	Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study. <i>Blood</i> , 2016, 128, 1143-1143.	0.6	26
81	Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study. <i>Blood</i> , 2016, 128, 1144-1144.	0.6	5
82	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Blood</i> , 2016, 128, 2293-2293.	0.6	2
83	Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study. <i>Blood</i> , 2016, 128, 244-244.	0.6	9
84	Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial. <i>Blood</i> , 2016, 128, 245-245.	0.6	10
85	A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial. <i>Blood</i> , 2016, 128, 2827-2827.	0.6	2
86	Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling. <i>Blood</i> , 2016, 128, 4407-4407.	0.6	2
87	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). <i>Blood</i> , 2016, 128, 4412-4412.	0.6	2
88	Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 678-678.	0.6	7
89	DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome. <i>Blood</i> , 2016, 128, 804-804.	0.6	1
90	Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0163291.	1.1	11

#	ARTICLE	IF	CITATIONS
91	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). Blood, 2016, 128, 4701-4701.	0.6	0
92	Functional Analysis of BTG1 and BTG2 Variants in Non-Hodgkin Lymphoma. Blood, 2016, 128, 1753-1753.	0.6	0
93	Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells. Blood, 2016, 128, 1660-1660.	0.6	0
94	Comparison of Two Rapid Predictive Methods for Therapeutic Targeting in Acute Myeloid Leukaemia Cells. Blood, 2016, 128, 1704-1704.	0.6	0
95	Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia. Blood, 2016, 128, 897-897.	0.6	0
96	Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood, 2015, 125, 2923-2932.	0.6	46
97	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34 ⁺ CD38 ^{low} blasts. British Journal of Haematology, 2015, 170, 80-84.	1.2	12
98	A randomized comparison of daunorubicin 90 mg/m ² vs 60 mg/m ² in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 2015, 125, 3878-3885.	0.6	230
99	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	3.8	136
100	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 392-399.	1.7	139
101	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 1295-1305.	5.1	433
102	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. Blood, 2015, 126, 189-189.	0.6	4
103	Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3111-3111.	0.6	1
104	Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). Blood, 2015, 126, 4399-4399.	0.6	3
105	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4364-4364.	0.6	0
106	Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials. Blood, 2015, 126, 320-320.	0.6	1
107	Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes. Blood, 2015, 126, 1944-1944.	0.6	0
108	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial. Blood, 2015, 126, 221-221.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. <i>Leukemia Research</i> , 2014, 38, 737-743.	0.4	7
110	A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2014, 124, 3747-3747.	0.6	0
111	Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3360-3368.	0.8	333
112	Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 4123-4131.	0.8	280
113	Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. <i>Haematologica</i> , 2013, 98, 172-178.	1.7	50
114	Equality Of Access To Transplant For Ethnic Minority Patients Through Use Of Cord Blood and Haploidentical Transplants. <i>Blood</i> , 2013, 122, 2138-2138.	0.6	2
115	Donor Attrition At The Confirmatory Typing Stage Results In Poorer Transplant Options For Patients Of All Ethnicities. <i>Blood</i> , 2013, 122, 3377-3377.	0.6	1
116	AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial. <i>Blood</i> , 2013, 122, 622-622.	0.6	24
117	Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3924-3931.	0.8	370
118	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	12.5	352
119	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. <i>Blood</i> , 2012, 120, 889-889.	0.6	4
120	Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4098-4098.	0.6	0
121	Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 369-377.	0.8	581
122	Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 2008-2008.	0.6	11
123	The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials. <i>Blood</i> , 2011, 118, 421-421.	0.6	0
124	Extracorporeal Photopheresis (ECP): Effective Therapy for Steroid Dependent and Refractory Acute Graft-Versus-Host Disease (GVHD). <i>Blood</i> , 2011, 118, 1973-1973.	0.6	0
125	European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2389-2395.	0.8	148
126	Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.. <i>Blood</i> , 2009, 114, 484-484.	0.6	11

#	ARTICLE	IF	CITATIONS
127	Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.. Blood, 2009, 114, 523-523.	0.6	1
128	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.. Blood, 2009, 114, 663-663.	0.6	24
129	The Telomerase Inhibitor RHPS4 Induces Telomere Shortening, DNA-Damage and Cell Death in AML Cells and Chemosensitises Cells to Daunorubicin.. Blood, 2009, 114, 2760-2760.	0.6	0
130	Impaired S Phase Arrest in AML Cells with a FLT3-ITD Treated with Clofarabine Allows Prolonged Drug exposure to Reverse the Chemoresistant Phenotype.. Blood, 2009, 114, 1000-1000.	0.6	0
131	Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 "Pick a Winner" Comparison.. Blood, 2009, 114, 486-486.	0.6	1
132	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.. Blood, 2009, 114, 1205-1205.	0.6	5
133	Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.. Blood, 2009, 114, 589-589.	0.6	71
134	Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT.. Blood, 2009, 114, 527-527.	0.6	0
135	High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry.. Blood, 2009, 114, 2286-2286.	0.6	0
136	Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. Blood, 2009, 114, 874-874.	0.6	0
137	A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica, 2008, 93, 405-412.	1.7	60
138	The Effect of ABC Transporters and FLT3 Status on the Activity of the Aurora Kinase B Inhibitor AZD1152 in AML Cells.. Blood, 2008, 112, 1627-1627.	0.6	1
139	Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 "Pick a Winner" Comparison. Blood, 2008, 112, 2962-2962.	0.6	4
140	Azacytidine and Gemtuzumab Ozogamicin Co-Operate to Inhibit the Wnt Pathway and Increase Cytotoxicity in AML. Blood, 2008, 112, 2991-2991.	0.6	3
141	Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party. Blood, 2008, 112, 451-451.	0.6	1
142	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. Blood, 2008, 112, 4413-4413.	0.6	0
143	The Effect of the CASP8 -6526N Del Promoter Polymorphism on Outcome in T-Cell Depleted Unrelated Donor Haemopoetic Stem Cell Transplants (HSCT). Blood, 2008, 112, 3001-3001.	0.6	0
144	A Polymorphism Study on Detoxification and DNA Repair Genes in 700 MDS Patients Demonstrates An Association Between Genotype and An Aberrant Karyotype. Blood, 2008, 112, 2690-2690.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10) Tj ETQq1 1 0.784314 rgBT /Overbo 566-566.	0.6	0
146	P-Glycoprotein Is Downregulated in KG1a Primitive Leukaemia Cells by LDL Cholesterol Deprivation and by HMG-CoA Reductase Inhibitors.. Blood, 2007, 110, 4192-4192.	0.6	0